Transaction #24297 · Form 4 · 0000902664-25-005396
TScan Therapeutics, Inc. · Purchase · Common Stock
TScan Therapeutics, Inc. · Transacted December 22, 2025 · Filed December 23, 2025
What does this filing report?
An SEC Form 4 filing for TScan Therapeutics, Inc. records a purchase involving Common Stock on December 22, 2025. The reported quantity was 75,500. The filing date is December 23, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- TScan Therapeutics, Inc.
- Company CIK
- 0001783328
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 75,500
- Reported price
- 0.9
- Reference value
- 67,950
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 8,012,916
- Ownership description
- See footnote
- SEC acceptance time
- Dec 23, 2025, 6:17 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Nichols Weston ↗
10% owner
CIK 0001746376
- Lynx1 Capital Management LP ↗
10% owner
CIK 0001910456
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8862 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- F2
- The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
- F3
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8958 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.